Pomalidomide, cyclophosphamide, and dexamethasone triplet therapy for relapsed/refractory multiple myeloma had an overall response rate of 76%.
Using separate indirect medication adherence measures, researchers determined adherence rates for patients with MM treated with oral immunomodulatory therapy.
An analysis of SEER data identified the risk for these cardiovascular events and the common related causes of death among patients with MM.
Researchers find trends among physical and emotional challenges associated with being the primary family caregiver of a patient with multiple myeloma.
Takeda will work with Memorial Sloan Kettering Cancer Center to develop CAR-T therapies for multiple myeloma.